Xaira Therapeutics, an AI-driven biotechnology startup that emerged earlier this year with a $1 billion funding round, continues to demonstrate its ambitions and staying power. Despite recent biotech industry turbulence, with some AI-focused biotech firms announcing layoffs and restructuring, Xaira has doubled down on growth. The firm is bolstering its leadership roster while announcing a planned planned relocation to the Gateway of Pacific III campus in South San Francisco. Xaira aims to engineer the drug discovery and development process through the end-to-end application of emerging AI technologies — albeit with higher-profile leadership and funding than other techbio firms.
A $1 billion launch amidst sector volatility
The scale of Xaira’s financing—with the support of Arch Venture Partners and Foresite Capital—is not only notable within biotech, but stands out across various sectors. As reported here in April, Xaira’s $1 billion funding round represents one of the largest private healthcare investments in recent memory, exceeded only by rare exceptions like Altos Labs’ $3 billion emergence in early 2022. The same article points out that while giant rounds are more common in semiconductors, AI, and data center infrastructure, healthcare has seen fewer mega-deals on this scale.
This year, only a handful of organizations raised more cash. Examples include established players outside of biotech such as xAI, which raised approximately $6 billion for supercomputer infrastructure, and OpenAI, which secured $6.6 billion in funding at a $157 billion valuation. Anthropic also made waves in the AI sector with an additional $4 billion investment from Amazon, bringing its total funding to $8 billion. Beyond pure AI companies, significant raises included Intersect Power, a clean energy developer that secured over $800 million with backing from Google, and Tenstorrent, a semiconductor startup that raised $693 million to advance its AI hardware solutions.
Xaira’s backers continue to bet big on the company’s ability to shorten and improve the drug discovery timeline. This confidence is reflected in the caliber of Xaira’s board, which includes former FDA Commissioner Scott Gottlieb, Nobel laureate Carolyn Bertozzi, and ex-J&J CEO Alex Gorsky. Investor sentiment remains robust even as the broader landscape has grown more cautious.
Leadership appointments and strategic repositioning
Paulo Fontoura
Chief Medical Officer (Effective early 2025): Dr. Paulo Fontoura joins after 16 years at Roche, where he oversaw translational medicine and clinical development for neuroscience, immunology, infectious disease, and rare disease therapies. With a track record of contributing to the approval of breakthrough medicines, Fontoura brings a wealth of clinical insight and experience with digital health innovations to Xaira’s pipeline.
Hetu Kamisetty, Ph.D.
Chief Technology Officer (Effective immediately): Dr. Hetu Kamisetty, a co-founder of Xaira and former Meta AI scientist, has been integral in scaling the company since 2023. He has deep expertise in machine learning, generative AI, and protein modeling—capabilities he honed while working in Dr. David Baker’s lab at the University of Washington. Kamisetty’s role will center on advancing foundational AI models such as RFDiffusion and ProteinMPNN to accelerate drug discovery and optimize computational design workflows.
Xaira’s current leadership bench includes Chief Scientific Officer Dr. Debbie Law and Chief People Officer Julia Tran. Together, they form a leadership cohort that spans clinical development, computational modeling, scientific strategy, and organizational dynamics—building blocks for a company that aspires to be a leader in driving AI-based biotech R&D.
New headquarters
Gateway Pacific III
Xaira’s decision to relocate to the Gateway of Pacific III campus situates the company at the heart of a prominent biotech ecosystem. Proximity to fellow innovators, academic institutions, and strategic partners in South San Francisco ensures that Xaira can access top-tier talent and collaborate on projects featuring emerging tech. The new facilities support closer integration between its Seattle-based teams—where foundational AI modeling occurs—and the Bay Area site, which houses expanded experimental capabilities and interdisciplinary collaborations.
For those interested in understanding how Xaira fits into the broader techbio landscape, consider exploring our extended coverage of 25 leading techbio organizations. While others trim their sails, Xaira is forging ahead, making bold moves that may define the next generation of computationally-powered drug discovery.
Filed Under: Data science, Drug Discovery and Development
